The rise of digital health alongside the transformation of reimbursement from fee-for-service to value-based care is allowing patients to fully participate in their own care, according to a leader with one of the top digital health companies in diabetes care.
The rise of digital health alongside the transformation of reimbursement from fee-for-service to value-based care is allowing patients to fully participate in their own care, according to a leader with one of the top digital health companies in diabetes care.
Janice McLeod, MA, RDN, LDN, CDE, FAADE, the director of Clinical Innovation for WellDoc, maker of the BlueStar digital therapeutic for type 2 diabetes (T2D), described the current landscape when asked what being an “e-educator” meant today, as she joined representatives from other digital health companies for a panel at the 2018 annual meeting of the American Association of Diabetes Educators (AADE).
“It is actually this convergence in digital therapeutics, and the rapid transition to value-based care, that together is creating this golden opportunity in healthcare transformation,” McLeod said. “Nowhere is that more needed than in diabetes.”
Like McLeod, fellow panelists Toby Smithson, MS, RDN, LDN, CDE, a diabetes lifestyle expert for Livongo Health, a diabetes management and coaching tool available through employers and health systems, and Rachel Head, RD, CDE, clinical operations manager for One Drop, a direct-to-consumer tool, described their frustration in former traditional roles. Trying to get patients what they needed, or being unable help them away from a hospital or care setting was “maddeningly frustrating,” said Head, who felt “that I was banging my head against the wall.”
Traditional reimbursement limits on diabetes education don’t meet current standards and fall far short of what patients need, the panelists said. Updated standards, also embraced by the American Diabetes Association, reflect the role that technology can play in giving patients coaching when they are making decisions—when it is most needed.
Smithson pointed to research that shows patients’ office visits with physicians don’t allow enough time to go over all the topics they want to discuss. “We need to find other opportunities,” she said.
Moderator Molly McElwee Malloy RN, CDE, clinical services manager for Tandem Diabetes Care, asked the panelists to further compare the effectiveness of digital health and the office visit.
McLeod described how AADE has played a leading role in gathering evidence on this topic, starting with a 2016 working group that led to a 2017 systematic review. “What they found was that these approaches were effective as long as they continued all the critical components,” including:
Read more about WellDoc’s BlueStar digital therapeutic technology for type 2 diabetes.
“Diabetes education is not ‘one and done.’ It doesn’t just occur every 3 months,” at an office visit,” McLeod said.
She highlighted the role of DANA, or Diabetes Advanced Network Access, the AADE’s technology and training site that helps members sort through the various categories of technology, from health and wellness apps that are not FDA regulated to digital therapeutics, which are under FDA purview.
Smithson and Head highlighted stories of real-life technology users who were able to do things like bring down their glycated hemoglobin (A1C) by 2% or avoid going on insulin through a combination of oral medications and coaching.
“Behavioral change doesn’t necessarily take place in a 30-minute visit,” said Head.
While digital health can help patients overcome multiple challenges—including the emotional and financial burdens of living with diabetes, geographic access to care, and the burdens on providers—the panelists noted that technology is not without its own barriers. It can hard to build rapport without eye contact. While the gap is closing, some seniors still struggle with it.
And reimbursement remains a challenge, McLeod said. If payers are serious about population health management, they should be serious about technology-enabled solutions, the panelists agreed.
“We need to be putting our thoughts and energy into, ‘How can I improve the health of the population in the most cost-effective way?’” McLeod said.
Semaglutide Eligibility Expands to Over Half of US Adults
November 21st 2024Over half of the US adult population may benefit from semaglutide, a drug primarily used for weight loss and diabetes, although concerns about access and cost persist, especially considering its potential for wider health applications.
Read More
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
Community Investment, Engagement Are Essential to Fully Address Cardiovascular Health Disparities
November 19th 2024Community-based researchers can teach clinicians a lot about how to best approach underserved populations disproportionately impacted by cardiovascular health complications.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen